Lanoxin

Digoxin, the active ingredient in Lanoxin, is a cardiac glycoside presented as an oral tablet for oral use. It is used to improve cardiac contractility in systolic heart failure and to control ventricular rate in atrial fibrillation and atrial flutter. GNH USA supplies Lanoxin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lanoxin (digoxin) acts on the cardiac conduction system and myocardial contractility to manage specific cardiovascular conditions.

Heart failure (systolic dysfunction): improves cardiac output and reduces symptoms of fatigue and dyspnea. Atrial fibrillation: provides rate control by slowing atrioventricular nodal conduction. Atrial flutter: assists in ventricular rate regulation and symptom relief.

Common Side Effects: - Nausea or vomiting - Diarrhea or abdominal discomfort - Fatigue or weakness - Blurred vision or visual halos - Headache - Dizziness

Serious or Rare Side Effects: - Life‑threatening arrhythmias (e.g., ventricular tachycardia) - Severe bradycardia or heart block - Marked electrolyte disturbances, especially hyperkalemia - Visual disturbances such as yellow‑green halos - Pulmonary edema in susceptible patients - Allergic skin reactions (rash, pruritus)

Before initiating therapy, clinicians should assess renal function, electrolyte status, and concomitant medications.

Renal function: adjust dose in patients with impaired clearance. Electrolyte balance: monitor potassium and magnesium levels closely. Thyroid disease: use cautiously in hyper‑ or hypothyroidism. Elderly patients: consider lower starting doses due to increased sensitivity. Therapeutic drug monitoring: obtain serum digoxin concentrations to avoid toxicity. Store at ambient temperature: keep tablets in the original container, protect from moisture and direct sunlight.

Digoxin has a narrow therapeutic index and interacts with several agents that can increase its serum concentration or potentiate its cardiac effects.

Major Interactions (Avoid): - Amiodarone: markedly raises digoxin levels. - Quinidine: increases digoxin concentration and risk of toxicity. - Verapamil: may cause excessive AV nodal slowing. - Spironolactone: potentiates digoxin's effects. - Macrolide antibiotics (e.g., erythromycin, clarithromycin): elevate serum digoxin.

Moderate Interactions (Monitor Closely): - Loop and thiazide diuretics: alter potassium and magnesium, affecting digoxin safety. - Beta‑blockers: additive AV‑node suppression may require rate monitoring. - ACE inhibitors or ARBs: can enhance digoxin's therapeutic effect and necessitate dose review.